Business
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 (“’2510”)
About this update from Immuneonco Biopharmaceuticals (shanghai) Inc Class H
[{"type":"image","alt":"Instil Bio","displaySize":"","headline":null,"caption":"Instil Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/38MAPe55bTDD07xl6tQzbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b","width":300,"height":157}},"lazy":false},{"type":"text","content":"US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025","length":81,"tagName":"p"},{"type":"text","content":"Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025","length":140,"tagName":"p"},{"type":"text","content":"DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 (“’2510”) by the U.S. Food and Drug Administration.","length":324,"tagName":"p"},{"type":"text","content":"Instil expects to initiate a phase 1 trial of ‘2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of ‘2510 in patients with solid tumors. Additionally, Instil continues to anticipate that initial safety and efficacy results from the ongoing phase 2 study of ‘2510 in combination with chemotherapy in first-line NSCLC in China will be shared in the second half of 2025 by ImmuneOnco.","length":530,"tagName":"p"},{"type":"text","content":"“We are pleased to announce the clearance of the ‘2510 IND by the FDA,” said Jamie Freedman, M.D., Ph.D., Chief Medical Officer of Instil. “Evaluating ‘2510 in a global population will be a critical milestone in the clinical development of ‘2510.”","length":247,"tagName":"p"},{"type":"text","content":"About Instil Bio","length":16,"tagName":"p"},{"type":"text","content":"Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF ...
More updates from Immuneonco Biopharmaceuticals (shanghai) Inc Class H